Drug Profile
Tadekinig alfa - AB2 Bio
Alternative Names: IL-18BP - AB2 Bio; r-hIL-18BP; Recombinant human IL-18 binding protein - AB2 BioLatest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator AB2 Bio
- Class Anti-inflammatories; Recombinant proteins
- Mechanism of Action Interferon gamma inhibitors; Interleukin 1 inhibitors; Interleukin 18 inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Immunological disorders
- Phase II Adult-onset Still's disease
Most Recent Events
- 02 Nov 2023 AB2 Bio completes phase-III trials in Immunological disorders (In adolescents, In children) in USA, Canada, Germany (SC) (NCT03113760)
- 07 Mar 2023 AB2 Bio plans to submit marketing authorization application
- 07 Mar 2023 AB2 Bio completes enrolment in its Phase-III clinical trials in Immunological disorders (In adolescents, In children) in USA, Canada, Germany (SC) (NCT03113760)